Aeterna Zentaris Inc. (AEZS): Price and Financial Metrics
GET POWR RATINGS... FREE!
AEZS Stock Summary
- AEZS has a higher market value than just 5.33% of US stocks; more precisely, its current market capitalization is $12,868,071.
- For AEZS, its debt to operating expenses ratio is greater than that reported by only 4.43% of US equities we're observing.
- With a year-over-year growth in debt of -55.5%, AETERNA ZENTARIS INC's debt growth rate surpasses only 4.54% of about US stocks.
- If you're looking for stocks that are quantitatively similar to AETERNA ZENTARIS INC, a group of peers worth examining would be BGRY, PTN, MNDO, BNOX, and PVCT.
- AEZS's SEC filings can be seen here. And to visit AETERNA ZENTARIS INC's official web site, go to www.zentaris.com.
AEZS Valuation Summary
- AEZS's price/sales ratio is 2; this is 57.45% lower than that of the median Healthcare stock.
- Over the past 243 months, AEZS's EV/EBIT ratio has gone up 16.8.
Below are key valuation metrics over time for AEZS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AEZS | 2023-03-17 | 2.0 | 0.3 | -1.0 | 3.0 |
| AEZS | 2023-03-16 | 2.0 | 0.3 | -1.0 | 3.0 |
| AEZS | 2023-03-15 | 2.0 | 0.3 | -1.0 | 3.1 |
| AEZS | 2023-03-14 | 2.0 | 0.3 | -1.0 | 3.0 |
| AEZS | 2023-03-13 | 1.9 | 0.3 | -0.9 | 3.1 |
| AEZS | 2023-03-10 | 2.0 | 0.3 | -1.0 | 3.0 |
AEZS Growth Metrics
- Its 3 year revenue growth rate is now at 173.94%.
- The year over year price growth rate now stands at -75.75%.
- The year over year net income to common stockholders growth rate now stands at -30.25%.
The table below shows AEZS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 6.628 | -12.669 | -13.462 |
| 2022-06-30 | 5.37 | -10.212 | -11.74 |
| 2022-06-30 | 5.37 | -10.212 | -11.74 |
| 2022-03-31 | 6.191 | -8.997 | -9.563 |
| 2021-12-31 | 5.26 | -8.581 | -8.368 |
| 2021-12-31 | 5.26 | -8.581 | -8.368 |
AEZS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AEZS has a Quality Grade of F, ranking ahead of 3.18% of graded US stocks.
- AEZS's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows AEZS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.128 | 0.366 | 4.492 |
| 2020-12-31 | 0.128 | 0.366 | 4.492 |
| 2019-12-31 | 0.024 | 0.229 | 2.567 |
| 2018-12-31 | 1.139 | 0.922 | -4.563 |
| 2018-12-31 | 1.139 | 0.922 | -4.563 |
| 2017-12-31 | 0.034 | 1.000 | 13.076 |
AEZS Stock Price Chart Interactive Chart >
AEZS Price/Volume Stats
| Current price | $2.64 | 52-week high | $9.75 |
| Prev. close | $2.72 | 52-week low | $2.54 |
| Day low | $2.61 | Volume | 5,600 |
| Day high | $2.72 | Avg. volume | 13,577 |
| 50-day MA | $3.37 | Dividend yield | N/A |
| 200-day MA | $4.04 | Market Cap | 12.82M |
Aeterna Zentaris Inc. (AEZS) Company Bio
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company was founded in 1991 and is based in Summerville, South Carolina.
Latest AEZS News From Around the Web
Below are the latest news stories about AETERNA ZENTARIS INC that investors may wish to consider to help them evaluate AEZS as an investment opportunity.
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue EstimatesAeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go decision milestones – Ongoing efforts to accelerate recruitment for our DETECT trial and establish partnering rights to Macrilen™ in the U.S. and Canada TORONTO, ONTARIO, March 23, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) |
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Pharmanovia, a global lifecycle management healthcare company, has acquired from th |
Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year. |
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year. |
AEZS Price Returns
| 1-mo | -20.72% |
| 3-mo | -14.29% |
| 6-mo | -32.65% |
| 1-year | -71.46% |
| 3-year | -80.80% |
| 5-year | -92.96% |
| YTD | -16.98% |
| 2022 | -64.20% |
| 2021 | -16.50% |
| 2020 | -53.24% |
| 2019 | -69.05% |
| 2018 | 24.58% |
Continue Researching AEZS
Want to see what other sources are saying about Aeterna Zentaris Inc's financials and stock price? Try the links below:Aeterna Zentaris Inc (AEZS) Stock Price | Nasdaq
Aeterna Zentaris Inc (AEZS) Stock Quote, History and News - Yahoo Finance
Aeterna Zentaris Inc (AEZS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...